TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from BioVersys AG ( (CH:BIOV) ).
BioVersys AG announced the release date for its Full-Year 2024 financial results, scheduled for March 26, 2025. The company will host a conference call and webcast to discuss financial outcomes, strategic outlook, and updates on its therapeutic pipeline, which could impact its operations and industry positioning.
More about BioVersys AG
BioVersys AG is a clinical stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of novel antibacterial products targeting serious infections caused by multidrug-resistant bacteria. Utilizing its TRIC and Ansamycin Chemistry platforms, BioVersys aims to overcome bacterial resistance and address unmet medical needs in antimicrobial and microbiome fields, with advanced programs targeting Acinetobacter baumannii and tuberculosis.
YTD Price Performance: -0.48%
Average Trading Volume: 10,465
For detailed information about BIOV stock, go to TipRanks’ Stock Analysis page.